Biofrontera AG has announced that it is negotiating fundamental changes to its cooperation with Biofrontera Inc. The discussions involve further adjustments to the existing license and supply agreement, including reducing the transfer price for products sold by the German Biofrontera Group in the US. Additionally, various strategic options are being considered, including a potential merger of the two companies. These negotiations may result in a significant shift in Biofrontera AG's business model and strategic direction. The announcement was made on June 10, 2025, by Biofrontera AG.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.